Abdullah GENÇ, Nesrin KARAMUSTAFALIOĞLU, Tevfik KALELİOĞLU

İki uçlu bozukluk ve inflamasyon

İki uçlu bozukluğun patofizyolojisinde inflamasyonun darol oynadığına dair çalışmalar ve bulgular giderek artmaktadır.Santral inflamasyonun yanı sıra sistemik immünyanıtın da hastalığın akut ve ötimik dönemleriyle veprognozla ilişkili olduğu düşünülmektedir. Bu derlemedeilk olarak immün sistem hücrelerinin sayısal ve yapısaldurumu gözden geçirilerek hastalığın dönemleriyle ilişkisinebakılacaktır. İnflamatuar yanıtta etkin rol oynayan vesistemik dolaşımda da ölçülebilen sitokinler incelenecektir.İnflamatuar belirteçlerin iki uçlu bozukluğun dönemleriyleilişkisinin yanı sıra iki uçlu bozukluk tedavileriyle değişimleride gözden geçirilecek ve üretimi sitokinler tarafındanindüklenen akut faz proteinlerinden de sözedilecektir.Yazımızın son kısmında iki uçlu bozuklukta anti-inflamatuarilaçların kullanımıyla ilgili çalışmalara değinilmiş ve gelecekçalışmalarla ilgili öneriler sunulmuştur.

Bipolar disorder and inflammation

There is growing number of researches showing evidenceabout the role of inflammation in pathophysiology ofbipolar disorder. Besides inflammation in central nervoussystem, systemic inflammation is also thought to beassociated with the acute and euthymic episodes andclinical outcome of illness. In this reviewö we firstlyfocus on the quantitative and structural changes inimmune cells and their relationship with the illnessepisodes. Also cytokines, which have an important role ininflammation and are measurable in systemic circulation,are summarized. In addition to changes of inflammatorymarkers in different episodes of bipolar disorder, wemention the effect of bipolar disorder treatments on thesemarkers. Acute phase proteins, which are produced andinduced by the effect of cytokines, are also reviewed.Finally, we discuss the role of anti-inflammatory agents intreatment of bipolar disorder and offer suggestions aboutfuture researches.

PDF

___

1. Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab. 2013;33(1):13-21. [CrossRef]
2. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337-41. [CrossRef]
3. Chen G, Reichlin S. Clearance of [125I]-tumor necrosis factoralpha from the brain into the blood after intracerebroventricular injection in rats. Neuroimmunomodulation. 1998;5(5):261-9. [CrossRef]
4. Gimsa U, Mitchison NA, Brunner-Weinzierl MC. Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediators Inflamm. 2013;2013:320519. [CrossRef]
5. Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol. 2012;92(5):959-75. [CrossRef]
6. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638-46. [CrossRef]
7. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384-92. [CrossRef]
8. Söderlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S, et al. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci. 2011;36(2):114-8. [CrossRef]
9. Acharjee S, Branton WG, Vivithanaporn P, Maingat F, Paul AM, Dickie P, et al. HIV-1 Nef expression in microglia disrupts dopaminergic and immune functions with associated mania-like behaviors. Brain Behav Immun. 2014;40:74-84. [CrossRef]
10. Kalelioglu T, Akkus M, Karamustafalioglu N, Genc A, Genc ES, Cansiz A, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as inflammation markers for bipolar disorder. Psychiatry Res. 2015;228(3):925-7. [CrossRef]
11. Çakır U, Tuman TC, Yıldırım O. Increased neutrophil/lymphoctye ratio in patients with bipolar disorder: a preliminary study. Psychiatr Danub. 2015;27(2):180-4.
12. Kalelioglu T, Tasdemir A, Genc A, Genc ES, Ozver I, Yesilbas D, et al. Complete blood count, kidney, liver function tests and other biochemical parameters in patients whom were under lithium monotherapy treatment. Journal of Mood Disorders (JMOOD). 2012;2(3):1. [CrossRef]
13. Cassidy F, Wilson WH, Carroll BJ. Leukocytosis and hypoalbuminemia in mixed bipolar states: evidence for immune activation. Acta Psychiatr Scand. 2002;105(1):60-4. [CrossRef]
14. Chrysanthou-Piterou M, Havaki S, Alevizos V, Papadimitriou GN, Issidorides MR. Chromatin ultrastructural abnormalities in leukocytes, as peripheral markers of bipolar patients. Ultrastruct Pathol. 2009;33(5):197-208. [CrossRef]
15. Banks WA. The Blood-Brain Barrier in Psychoneuroimmunology. Neurol Clin. 2006;24(3):413-9. [CrossRef]
16. Mitchell RHB, Goldstein BI. Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. J Am Acad Child Adolesc Psychiatry. 2014;53(3):274-96. [CrossRef]
17. Altamura AC, Buoli M, Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin Neurosci. 2014;68(1):21-36. [CrossRef]
18. Sözeri-Varma G. Neuroinflammatory Hypothesis in Major Depressive Disorder. Psikiyatr Guncel Yaklasimlar - Curr Approaches Psychiatry. 2014;6(1):1-9. [CrossRef]
19. Barbosa IG, Huguet RB, Mendonça VA, Sousa LP, Neves FS, Bauer ME, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2011;261(2):139-43. [CrossRef]
20. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214-7. [CrossRef]
21. Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ. Cytokine levels in euthymic bipolar patients. J Affect Disord. 2010;126(3):458- 62. [CrossRef]
22. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun. 2011;25(6):1206-13. [CrossRef]
23. Panizzutti B, Gubert C, Schuh AL, Ferrari P, Bristot G, Fries GR, et al. Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker? J Affect Disord. 2015;182:64-9. [CrossRef]
24. Chou Y-H, Hsieh W-C, Chen L-C, Lirng J-F, Wang S-J. Association between the serotonin transporter and cytokines: Implications for the pathophysiology of bipolar disorder. J Affect Disord. 2016;191:29-35. [CrossRef]
25. Barbosa IG, Rocha NP, de Miranda AS, Magalhães PV da S, Huguet RB, de Souza LP, et al. Increased levels of adipokines in bipolar disorder. J Psychiatr Res. 2012;46(3):389-93. [CrossRef]
26. Barbosa IG, Rocha NP, Huguet RB, Ferreira RA, Salgado JV, Carvalho LA, et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord. 2012;137(1-3):151-5. [CrossRef]
27. Remlinger-Molenda A, Wojciak P, Michalak M, Karczewski J, Rybakowski JK. Selected cytokine profiles during remission in bipolar patients. Neuropsychobiology. 2012;66(3):193-8. [CrossRef]
28. Fiedorowicz JG, Prossin AR, Johnson CP, Christensen GE, Magnotta VA, Wemmie JA. Peripheral inflammation during abnormal mood states in bipolar I disorder. J Affect Disord. 2015;187:172-8. [CrossRef]
29. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res. 2011;45(12):1608-16. [CrossRef]
30. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun. 2009;23(8):1079-82. [CrossRef]
31. Valvassori SS, Tonin PT, Varela RB, Carvalho AF, Mariot E, Amboni RT, et al. Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine. Bipolar Disord. 2015;17(5):507-17. [CrossRef]
32. Tonin PT, Valvassori SS, Lopes-Borges J, Mariot E, Varela RB, Teixeira AL, et al. Effects of ouabain on cytokine/chemokine levels in an animal model of mania. J Neuroimmunol. 2014;276(1-2):236- 9. [CrossRef]
33. Ortiz-Domínguez A, Hernández ME, Berlanga C, GutiérrezMora D, Moreno J, Heinze G, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596-602. [CrossRef]
34. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2-3):263-7. [CrossRef]
35. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004;150(1-2):116-22. [CrossRef]
36. Tsai SY, Chen KP, Yang YY, Chen CC, Lee JC, Singh VK, et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry. 1999;45(8):989-94. [CrossRef]
37. Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE, et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004;129(3):267-72. [CrossRef]
38. Su KP, Leu SJC, Yang YY, Shen WW, Chou YM, Tsai SYM. Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. J Affect Disord. 2002;71(1- 3):205-9. [CrossRef]
39. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PVS, KauerSant'Anna M, Klamt F, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 2011;45(2):156-61. [CrossRef]
40. Mota R, Gazal M, Acosta BA, de Leon PB, Jansen K, Pinheiro RT, et al. Interleukin-1ß is associated with depressive episode in major depression but not in bipolar disorder. J Psychiatr Res. 2013;47(12):2011-4. [CrossRef]
41. Monfrim X, Gazal M, De Leon PB, Quevedo L, Souza LD, Jansen K, etal. Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1ß? Bipolar Disord. 2014;16(7):741-7. [CrossRef]
42. Guloksuz S, Altinbas K, Aktas Cetin E, Kenis G, Bilgic Gazioglu S, Deniz G, et al. Evidence for an association between tumor necrosis factor-alpha levels and lithium response. J Affect Disord. 2012;143(1-3):148-52. [CrossRef]
43. Himmerich H, Bartsch S, Hamer H, Mergl R, Schönherr J, Petersein C, et al. Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro. J Psychiatr Res. 2013;47(11):1751-9. [CrossRef]
44. Ichiyama T, Okada K, Lipton JM, Matsubara T, Hayashi T, Furukawa S. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res. 2000;857(1- 2):246-51. [CrossRef]
45. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29(2):141-52. [CrossRef]
46. Kim Y-K, Jung H-G, Myint A-M, Kim H, Park S-H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1-3):91-5. [CrossRef]
47. Li H, Hong W, Zhang C, Wu Z, Wang Z, Yuan C, et al. IL-23 and TGF-ß1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. J Affect Disord. 2015;174:361-6. [CrossRef]
48. Avramopoulos D, Pearce BD, McGrath J, Wolyniec P, Wang R, Eckart N, et al. Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation. PLoS One. 2015;10(3):e0116696. [CrossRef]
49. Wium-Andersen MK, Ørsted DD, Nordestgaard BG. Elevated C-reactive protein and late-onset bipolar disorder in 78 809 individuals from the general population. Br J Psychiatry. 2016;208(2):138-45. [CrossRef]
50. Chung K-H, Huang S-H, Wu J-Y, Chen P-H, Hsu J-L, Tsai S-Y. The link between high-sensitivity C-reactive protein and orbitofrontal cortex in euthymic bipolar disorder. Neuropsychobiology. 2013;68(3):168-73. [CrossRef]
51. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150(2):456- 9. [CrossRef]
52. Cunha AB, Andreazza AC, Gomes FA, Frey BN, da Silveira LE, Gonçalves CA, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258(5):300-4. [CrossRef]
53. De Berardis D, Conti CM, Campanella D, Carano A, Scali M, Valchera A, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol. 2008;21(2):319-24. [CrossRef]
54. Huang T-L, Lin F-C. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):370-2. [CrossRef]
55. Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik MS. Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment. Psychiatry Res. 2015;228(3):386-92. [CrossRef]
56. Bai Y-M, Su T-P, Tsai S-J, Wen-Fei C, Li C-T, Pei-Chi T, et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord. 2014;166:187-92. [CrossRef]
57. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):952-5. [CrossRef]
58. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17(4):175-9. [CrossRef]
59. Chiarani F, Tramontina JF, Ceresér KM, Kunz M, Paim L, Vargas CR, et al. Homocysteine and other markers of cardiovascular risk during a manic episode in patients with bipolar disorder. Rev Bras Psiquiatr (São Paulo, Brazil). 1999;35(2):157-60. [CrossRef]
60. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997;66(1):1-11. [CrossRef]
61. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87- 94. [CrossRef]
62. Kargar M, Yousefi A, Mojtahedzadeh M, Akhondzadeh S, Artounian V, Abdollahi A, et al. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Med Wkly. 2014;144:w13880. [CrossRef]
63. Stolk P, Souverein PC, Wilting I, Leufkens HGM, Klein DF, Rapoport SI, et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids. 2010;82(1):9-14. [CrossRef]
64. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74(1):15-25. [CrossRef]
65. Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord. 2009;11(7):726-34. [CrossRef]